Fig. 4

Fitness of the dual tropic HIV-1 isolate when blocking the virus component using CCR5 or CXCR4. a The primary dual tropic HIV-1 isolates were competed against the x4 [50] titereds (all titered on U87.CD4.CXCR4 cells) in U87.CD4.CXCR4 cultures or in PHA-stimulated, IL-2 treated PBMC cultures with or without maraviroc. The fitness differences are plotted as described in Fig. 2 and in the “Methods”. b The level of maraviroc inhibition of the monoinfections or dual infections was measured by relative RT activity in the cell free supernatant and plotted as a percentage of the no drug control. c The primary dual tropic HIV-1 isolates and r5 reference strains were also titered on U87.CD4.CCR5 cells and then competed together in PHA-stimulated, IL-2 treated PBMC cultures with or without AMD3100. The same dual infection with the same MOI (0.004) was repeated in U87.CD4.CCR5 cultures. The fitness differences are plotted as described in Fig. 2 and “Methods”. d The level of AMD3100 inhibition of the monoinfections or dual infections was measured by relative RT activity in the cell free supernatant and plotted as a percentage of the no drug control. All experiments were performed in triplicate with the exception of c, d (performed in duplicate) due to limited supply of AMD3100.